Ukrainian pharmaceuticals: Darnitsa
- Дата выхода отчёта: 16 октября 2007 г.
- География исследования: Украина
- Период исследования: 2007 (актуализация по запросу)
- Язык отчёта: Английский
- Способ предоставления: электронный
-
Содержание
1. INVESTMENT CASE
BUSINESS PROFILE
Executive summary
Valuation summary
5. Ukrainian Pharmaceutical Market
Underpenetrated, double growth by 2010
Product mix: Generics and OTC prevail
Competition
Market drivers
Higher consumer incomes
Increasing government spending
Mandatory GMP compliance
Introduction of medical insurance
Legal environment and regulations
6. The Company
Market position
Product mix
Production facilities
Cost structure
Cost advantages
Distribution
CapEx program
Management strategy
Compliance with GMP requirements
Optimizing product mix
Growth through acquisitions
Arterium Corporation
Farmak
BCPP
Approaching new geographical markets
Risks
Legal structure
Management team
7. Valuation
Peer comparison
DCF valuation
Comparable deals
Financial summary
Glossary
CHARTS
Share price performance, USD
Top 10 players in the Ukrainian pharma market
Valuation summary chart, USD per share
Ukrainian pharmaceutical market, 2004-2015E
Market segmentation, 2006
How Ukrainians seek medical help
Price differentiation
Market shares of imported and domestic drugs, 2006
Market concentration, Ukraine vs. Europe
Top-20 companies in Retail pharma market, 2006
Top-20 companies in the Hospital segment, 2006
Per-capita medical drug consumption and market growth potential
Disposable income
Growth of avg. prices vs. entire market, USD bln
Changes in price distribution
Healthcare expenditures as a % of GDP
Darnitsa's market share, 2006
Price trends: local drugs vs. imported
Market & revenue breakdown by therapeutic category, 2006
Top-5 categories on the market and in Darnitsa sales, 2005-1H07
Cost of goods sold, 2006
Producers recognition by distributors (curved)
The number of visits to doctors by Darnitsa representatives
Structure of the holding
The effect of GMP implementation on Darnitsa's revenue
Darnitsa's revenue growth, USD mln
Darnitsa's gross margin forecast
TABLES
MARKET INFORMATION
STOCK OWNERSHIP
KEY FINANCIALS
KEY RATIOS
Selected cross-border deals in 2006-2007
Valuation summary table
Pharmaceutical market by therapeutic category, 2006
Drugs distribution by price, 2006
Top-4 domestic producers of pharmaceuticals
Darnitsa revenue splits
Revenue breakdown by product form
Product launches, 2004-1H07
Darnitsa partnerships
Production shops
Operating cost, 2006
Top-10 distributors of Darnitsa's products in Ukrainian market
Sales breakdown by destination
Investment program
Contribution of new products to revenue growth, 2006
Top-priority product pipeline
Prospective pipeline
Branded vs. non-branded products
Darnitsa's export pipeline: products pending for approval
Functions performed by group companies
Peer valuation summary
Detailed peer data
Macro and market assumptions
DCF output
Sensitivity of Darnitsa's 12M equity value, USD mln
M&A deals in the CEE and CIS pharmaceutical sector, 2006-2007 (USD mln)
Income statement, USD mln
Balance sheet, USD mln
Cash flow statement, USD mln
Exchange Rates, UAH/USD
